GLP-1 Medications and Eating Disorders: 2026 Research

Do GLP-1 medications and eating disorders mix? The short answer: carefully, and sometimes not at all. These drugs turn down appetite. For most people that helps. For someone with a restrictive eating disorder, the same effect can feed the illness. In October 2026 a group of 45 experts published the first consensus rules: screen everyone before starting, avoid the drugs in current restrictive eating disorders, and watch closely when there is a past history.

This guide covers what the newest research found, who the experts say should avoid these drugs, the warning signs, and how to protect your body if you do take one.

Why GLP-1 eating disorder concerns are in the news

Several things landed close together in 2026:

• A JAMA Psychiatry research letter by Nicholas Peiper and colleagues at the University of Louisville surveyed people with eating disorders about GLP-1 use (reported by Healio on August 3, 2026).
• A World Psychiatry paper by Keshen and colleagues gave the first expert consensus on GLP-1s in eating disorders (October 2026).
• On October 30, 2026, MIT Technology Review reported that new JAMA Psychiatry estimates show the global incidence of anorexia and bulimia rose 71% from 1990 to 2023, and asked whether GLP-1s could make things worse.

Clinicians also report a pattern: people with a history of restriction who see the drug as a way to eat even less. That is the core worry. The drug is not doing anything unusual. It does exactly what it is built to do, in a person for whom less food is the problem.

How many people with eating disorders use GLP-1s?

The JAMA Psychiatry survey ran online from December 2025 to January 2026 and included 436 people with eating disorders. Here is what it found.

Use was very different by diagnosis:

The researchers compared this with about 15% lifetime use in the general public. The lead author called the estimates "probably conservative." Keep the limits in mind: it was an online survey, most people in it were white women, and it cannot show whether the drugs caused any eating disorder.

The atypical anorexia number stands out. People with atypical anorexia restrict food and lose a lot of weight but are not underweight, so they may be able to get a prescription that a very thin person could not.

A separate 2026 records study found about 1.1 million US adults got a GLP-1 without an approved reason in their charts, and eating disorder history was about six times more common in that group. See our guide to GLP-1 off label use.

Can GLP-1 medications cause eating disorders?

Nobody knows yet. What the research shows so far:

• The concern is real. For restrictive eating disorders, lower appetite, early fullness and nausea can make it easier to restrict and harder for a care team to see what is going on.
• Proof is missing. There are almost no controlled studies on GLP-1s in restrictive eating disorders. The World Psychiatry experts asked for long-term studies to learn whether the drugs raise, lower or do not change the risk of a new eating disorder.

So the honest answer is: the risk looks highest for people who already have, or once had, a restrictive eating disorder. For people with no history, there is no clear evidence of a new risk, but nobody should ignore early signs.

Can GLP-1 help with binge eating disorder?

Possibly, for some people. GLP-1s are not approved for binge eating disorder, and the trials are small. A 2025 meta-analysis in Eating and Weight Disorders pooled 5 studies with 182 people. Compared with control groups, GLP-1 users had:

• Binge Eating Scale scores 8.14 points lower
• BMI 1.48 points lower
• Weight 3.81 kg (about 8.4 lb) lower

The authors said the data are limited and more trials are needed. The consensus experts also noted that the strongest study design they reviewed found no significant drop in binge episodes with liraglutide compared with placebo, even though weight loss was larger. Our GLP-1 for binge eating disorder guide covers that side in more depth.

What the 2026 expert rules say

The World Psychiatry consensus brought together 45 clinicians, researchers and people with lived experience. Its main points, in plain English:

If your prescriber did not ask about eating history before writing your prescription, you can bring it up yourself. For families weighing these drugs for someone under 18, our GLP-1 for teens guide lists which ones the FDA allows and from what age. A short, honest answer helps them pick the right plan and the right check-in schedule.

Warning signs to watch for on a GLP-1

Lower appetite is the point of these drugs. These signs go beyond that and are worth telling your prescriber about:

• Skipping whole meals on purpose, not just eating smaller ones
• Feeling relieved or proud when you cannot eat
• Wanting a higher dose, or getting the drug from somewhere other than your prescriber, to eat even less
• Fear of any weight regain that takes over your day
• Using the shot or pill to make up for a meal you ate
• Dizziness, fainting, hair loss you did not expect, or feeling cold all the time
• Hiding how little you eat from people close to you

Mood matters here too. Our guide to GLP-1 and mood explains what to watch for. If you have thoughts of harming yourself, call or text 988 in the US. If you faint or have chest pain, call 911.

Teens, people who are pregnant, and anyone with a current eating disorder need a doctor's care for this decision. This guide is not a substitute for that.

Not eating on GLP-1: how to protect your body

For people who are cleared to take a GLP-1, the most common problem is not an eating disorder. It is simply eating too little protein while appetite is low. That leads to muscle loss, weakness and slower recovery.

A safer frame than "eat as little as possible" is to set a floor, not a ceiling:

• A daily protein floor. Our protein target guide explains how to set one.
• Regular meal times, even when you are not hungry. Small, planned meals beat skipping.
• Strength training two or three times a week to tell your body to keep its muscle.
• Handling nausea so it does not become a reason to stop eating. See managing nausea on Ozempic.

This is where Sharpy is built to help. It does not count calories or set a calorie limit. It gives you one protein target, one 20-minute workout and one Shape Score a day, so the focus stays on keeping muscle. If any tracking makes you anxious or pulls you toward restriction, skip apps and work with your care team instead. That is the right call.

Questions to ask your prescriber

• Should I be screened for an eating disorder before I start?
• With my history, how often will we check in, and what will we check?
• What is a healthy pace of weight loss for me?
• What should I do if I am eating much less than you expect?
• Can my therapist or dietitian be part of the plan?

The bottom line

GLP-1 medications and eating disorders sit at a tricky crossroads. For many people with obesity or diabetes, these drugs are a real help. For people with current restrictive eating disorders, the 2026 expert advice is to avoid them, and for anyone with a past history, to go slowly with close follow-up. Whatever your situation, aim to eat enough, especially protein, and keep your muscle. Sharpy keeps that daily plan simple: protein, a short workout, and a Shape Score.

Sources

• Healio: About 10% of patients with eating disorders have misused GLP-1 receptor agonists (JAMA Psychiatry research letter, Peiper et al.), Aug 3, 2026
• Keshen et al., Consensus-based recommendations for GLP-1 receptor agonists in the context of eating disorders: a modified Delphi study, World Psychiatry, 2026 (summary by Riccardo Dalle Grave, Psychology Today, Oct 26, 2026)
• Radkhah et al., GLP-1 agonists in the treatment of eating disorders: a systematic review and meta-analysis, Eating and Weight Disorders, 2025
• MIT Technology Review: Eating disorders are on the rise. GLP-1s could make things worse, Oct 30, 2026